Chemical Biology and Drug Design

OCTOBER 25, 2023

UAN rats possessed prominent levels of serum creatinine, UA, cys-C, and NGAL, which all reduced after hispidulin treatment in a dose-dependent manner. HE staining determined the improvement of kidney injury after treatment, which was comparable to the efficacy of febuxostat.

Treatment 100

Treatment Drugs Research 100

Drug Target Review

JUNE 9, 2023

This exclusive interview with Dr Sharon Benzeno, Chief Commercial Officer, Immune Medicine at Adaptive Biotechnologies, unveils some ground-breaking research on T- cell therapy for cancer , which has seen the first TCR-based therapeutic candidate progress to clinical development, offering promising advancements in innovative cancer treatments.

Treatment 106

Treatment Packaging Clinical Research Therapies 106

PLOS: DNA Science

MARCH 28, 2024

FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. A Scant Protein with Outsize Importance Slowing the muscle decline of DMD presents two huge challenges: the ubiquity of muscle and a giant gene. The gene presents a complex landscape. million DNA bases.

FDA Approval 98

FDA Approval Treatment FDA DNA 98

Common Sense for Drug Policy Blog

DECEMBER 16, 2023

Treatment for Methamphetamine Use "Methamphetamine is a highly addictive psychostimulant with evidence of neurotoxic properties ( 1 – 3 ) and is consistently ranked as one of the most harmful illicit substances—both to the person using and to society ( 4 , 5 ). 33.8) ( 18 )." 33.8) ( 18 )." Psychiatry 14:1123424. doi: 10.3389/fpsyt.2023.1123424

Treatment 52

Treatment Therapies Research Drugs 52

National Drug & Alcohol Research Centre Blog

DECEMBER 4, 2023

Kendal Chidwick NDARC’s Kendal Chidwick discusses the findings from a recently published study that examined how patterns of opioid agonist treatment medicines have changed over the past decade. Other changes around this time aimed at improving treatment accessibility included increased use of take-home doses and telehealth appointments.

Treatment 133

Treatment Community Pharmacies Pharmacy International 133

The Pharma Data

FEBRUARY 24, 2022

Allergan, an AbbVie (NYSE: ABBV) company, today announced new data to be presented from Allergan’s leading portfolio of eye care treatments at the 2022 American Glaucoma Society (AGS) Annual Meeting being held in Nashville, TN and virtually from March 3-6. Robinson, M.D.,

Treatment 52

Treatment FDA Approval FDA Production 52

SCIENMAG: Medicine & Health

JUNE 8, 2023

ECU Centre for Precision Health Clinical Professor Adnan Khattak presented the trial’s latest results at the 2023 American Society of Oncology (ASCO) congress in Chicago this week, the biggest […]

Treatment 90

Treatment Vaccine Trials Research 90

SCIENMAG: Medicine & Health

JUNE 17, 2023

CHICAGO—By being undiagnosed or untreated, a significant fraction of people with obesity or overweight are not getting the recommended care, despite an increase in new treatment options, according to research being presented on June 17 at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

Treatment 66

Treatment Research 66

SCIENMAG: Medicine & Health

JUNE 17, 2023

Houston, TX – New research by investigators in Ghent, Belgium shows that intravenous treatment with MK-3402, a metallo-beta-lactamase inhibitor, can be an effective strategy in fighting antimicrobial resistance. The findings are presented at ASM Microbe 2023, the annual meeting of the American Society for Microbiology.

Treatment 62

Treatment Research 62

SCIENMAG: Medicine & Health

OCTOBER 4, 2023

Type of work: peer-reviewed/clinical trial/people Credit: Eurostat Type of work: peer-reviewed/clinical trial/people A major clinical trial shows that the drug, esketamine, one of the two main forms of ketamine, outperforms one of the standard treatments for treatment-resistant major depression.

Treatment 52

Treatment Clinical Trials Drugs Trials 52

The Pharma Data

NOVEMBER 23, 2021

Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. Data presented at ASH by Roche span multitudinous blood conditions, including carcinoma, leukaemia, multiple myeloma and haemophilia.

Treatment 52

Treatment Drugs Trials Production 52

Drug Target Review

OCTOBER 25, 2023

Their findings may result in new treatments for reproductive conditions. He stated that this could inform new treatments for reproductive conditions like recurrent pregnancy loss and preeclampsia. Preeclampsia may present at any gestation but is more commonly encountered in the third trimester.

Treatment 106

Treatment Virus Research Science 106

SCIENMAG: Medicine & Health

JUNE 16, 2023

The use of thyroid hormones other than the commonly prescribed hormone medicine levothyroxine to treat hypothyroidism, or underactive thyroid, is increasing, according to a study being presented Friday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.

Treatment 59

Treatment 59

The Pharma Data

MAY 14, 2021

Product Name: Weight Dissolver – Video Presentation. Click here to get Weight Dissolver – Video Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. CLICKBANK partiesâ??)

Production 52

Production Compliance Testimonials Regulations 52

Broad Institute

SEPTEMBER 7, 2023

EWSC: Foundation models for therapeutic design and treatment prediction By Rose Circeo September 7, 2023 Breadcrumb Home EWSC: Foundation models for therapeutic design and treatment prediction EWSC-MIT EECS Joint Colloquium Series Presented by Eric and Wendy Schmidt Center Marinka Zitnik Foundation models for therapeutic design and treatment prediction (..)

Treatment 52

Treatment Engineering Science 52

The Pharma Data

MARCH 9, 2021

and Shionogi Limited as shareholders, presented positive data from its phase IIa proof-of-concept study of the investigational maturation inhibitor GSK3640254 (GSK’254). These findings were presented today at the (virtual) 2021 Conference on Retroviruses and Opportunistic Infections (CROI). Kimberly Smith, M.D., Kimberly Smith, M.D.,

Treatment 52

Treatment RNA Pharmacokinetics Virus 52

Drug Target Review

AUGUST 29, 2024

However, these treatments will eventually fail for the majority of patients, so there is a strong need for better CAR therapies. How might the CD5 knockout approach impact the treatment of other types of cancers beyond T-cell lymphoma?

Therapies 59

Therapies Treatment Engineering Molecular Biology 59

The Pharma Data

MARCH 8, 2021

The data were presented at the 28th Conference on Retroviruses and Opportunistic Infections ( virtual CROI 2021). No treatment-emergent resistance to any components of Biktarvy occurred in participants treated with Biktarvy. BOXED WARNING: POST TREATMENT ACUTE EXACERBATION OF HEPATITIS B. Study 1489 and Study 1490 are ongoing.

Treatment 52

Treatment Therapies RNA Laboratories 52

SCIENMAG: Medicine & Health

MARCH 28, 2024

DETROIT – A groundbreaking study published in the journal iScience presents crucial insights into the ocular effects of Zika virus infection during pregnancy and offers promising avenues for therapeutic intervention.

Virus 67

Virus Treatment Research 67

SCIENMAG: Medicine & Health

JULY 31, 2023

PDT CONTACT: Camille Jewell cjewell@vancomm.com or 202-248-5460 Research Shows Filter Tip Stent Retrievers May Allow Neurointerventionalists to Remove Blood Clots on the First Try During Stroke Treatment SAN DIEGO—Research presented today at the Society of NeuroInterventional Surgery’s (SNIS) 20th Annual Meeting shows that different types […] (..)

Treatment 71

Treatment Research 71

The Pharma Data

MAY 15, 2021

Product Name: Dentitox Pro – Text Presentation. Click here to get Dentitox Pro – Text Presentation at discounted price while it’s still available… All orders are protected by SSL encryption – the highest industry standard for online security from trusted vendors. Dentitox Pro is non-GMO and safe. Read more here.

Production 52

Production Packaging Nurses FDA Approval 52

The Pharma Data

SEPTEMBER 6, 2021

First data to be presented from the phase II coopERA Breast Cancer study evaluating neoadjuvant giredestrant treatment for oestrogen receptor (ER)-positive, HER2-negative breast cancer. Roche’s Chief Medical Officer and Head of Global Product Development. Lung Cancer Highlights.

Treatment 52

Treatment Therapies DNA Trials 52

The Pharma Data

JUNE 7, 2023

The research presented reinforces the efficacy of LUMAKRAS ® /LUMYKRAS ® (sotorasib) in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC). Reese, M.D., executive vice president of Research and Development at Amgen.

Clinical Trials 40

Clinical Trials Trials Treatment Disease 40

Drug Target Review

JULY 12, 2023

Molecular-level biochemical assays like transcriptomics, genomics and proteomics have emerged as valuable tools for identifying potential targets in cancer treatment through deep cyclic inhibition (DCI). How does the DCI mechanism compare to the design of other drugs for cancer treatment?

Biochemical Assays 98

Biochemical Assays Treatment Bioinformatics Disease 98

The Pharma Data

JANUARY 7, 2021

. – January 8, 2021) – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase 2021 and will be presenting the strategic plan for long-term growth. .

Pharmaceutical Companies 52

Pharmaceutical Companies Therapies Science Pharmaceuticals 52

ASPET

SEPTEMBER 22, 2023

These results suggest that brain damage can be long-lasting or permanent if nerve agent-induced SE in infant victims is treated with midazolam at a delayed timepoint after SE onset, while antiglutamatergic treatment with tezampanel and caramiphen provide significant neuroprotection.

Treatment 100

Treatment FDA Drugs 100

The Pharma Data

JULY 29, 2021

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 Alzheimer’s Association International Conference (AAIC) . United States and virtually from July 26 to 30, 2021 (Presentation No.:

Clinical Trials 52

Clinical Trials Treatment Clinical Development Disease 52

The Pharma Data

APRIL 11, 2023

Bayer is progressing novel research around its prostate cancer treatment darolutamide. The presentation highlights the synergistic anti-cancer effects of a PSMA (prostate-specific membrane antigen)-actinium-225 conjugate in combination with darolutamide in preclinical prostate cancer models.

Research 40

Research Clinical Trials Small Molecule Trials 40

The Pharma Data

AUGUST 30, 2021

Basel, August 30, 2021 — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and investigator-initiated trials accepted at the upcoming European Society for Medical Oncology (ESMO) Congress 2021. 19, 2:10 PM CEST].

Trials 52

Trials Clinical Trials Production Therapies 52

The Pharma Data

OCTOBER 27, 2020

Cowen Virtual Presentation Series – 2020 IO Next Summit at 1:15 p.m. (NASDAQ: REGN ) will webcast management participation as follows: Credit Suisse 29 th Annual Virtual Healthcare Conference at 8:45 a.m. EST on Monday, November 9, 2020. EST on Friday, November 13, 2020. Jefferies Virtual London Healthcare Conference at 7:20 a.m.

FDA Approval 52

FDA Approval Laboratories Disease Pharmaceuticals 52

ASPET

SEPTEMBER 20, 2024

The present studies evaluated the reinforcing effects of both compounds in monkeys under several conditions. Recently, several modafinil analogues reduced cocaine SA in rats and monkeys, including JJC8-088, characterized as "cocaine like" in rats, and JJC8-091, characterized as "atypical" and not SA by rats. mg/kg/injection), and JJC8-091 (0.1-3.0

FDA Approval 100

FDA Approval Treatment FDA Drugs 100

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Trials Disease Hospitals 52

The Pharma Data

APRIL 28, 2022

Researchers at Karolinska Institutet in Sweden have now developed a method for identifying the immune cells involved in autoimmune diseases, and have identified four new target molecules of potential significance for future personalised treatment of MS. This way of creating personalised treatment is called precision medicine.

Treatment 52

Treatment Disease Research Science 52

The Pharma Data

MAY 31, 2022

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present data at two upcoming scientific congresses this spring: the 58 th Annual Meeting of the American Society of Clinical Oncology (ASCO) , June 3-7 in Chicago, Ill. Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “In

Research 40

Research Pharmaceutical Companies Therapies Pharmaceuticals 40

The Pharma Data

NOVEMBER 9, 2021

Donations include the impact of treatment with bulevirtide, an investigational treatment for people with habitual hepatitis delta contagion (HDV) in theU.S. Donations include the impact of treatment with bulevirtide, an investigational treatment for people with habitual hepatitis delta contagion (HDV) in theU.S.

Disease 52

Disease Clinical Trials Treatment Pharmacokinetics 52

Common Sense for Drug Policy Blog

FEBRUARY 20, 2024

Prescriber Attitudes, Beliefs, Stigma, and Treatment of Opioid Use Disorder "A study in Canada found that personal beliefs of NPs often pose a barrier to providing treatment, for example, views such as patients with OUD deserve less care than other patients [ 12 ], this was also reported as a barrier in the study by Spetz and colleagues [ 31 ].

Treatment 40

Treatment Nurses Pharmacy Doctors 40

The Pharma Data

MAY 22, 2023

DUPIXENT® (DUPILUMAB) LATE-BREAKING PHASE 3 COPD RESULTS PRESENTED AT ATS AND SIMULTANEOUSLY PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE Regeneron Pharmaceuticals, Inc. The Dupixent Phase 3 results were presented in the 2023 American Thoracic Society (ATS) International Conference session “New England Journal of Medicine and JAMA.

Trials 52

Trials Disease Clinical Trials Therapies 52